{
    "cancer_info": {
        "cancer_name": "Hairy Cell Leukemia"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Bone Marrow Biopsy/Aspirate",
            "Immunophenotyping (Flow Cytometry/IHC)",
            "Molecular Testing: BRAF V600E mutation",
            "Molecular Testing: IGHV4-34 rearrangement",
            "History/Physical Exam",
            "CBC with differential",
            "Comprehensive metabolic panel",
            "LDH testing",
            "Hepatitis B/C testing",
            "Peripheral blood smear",
            "CT chest/abdomen/pelvis with contrast (if symptomatic)",
            "Fertility Preservation discussion"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Asymptomatic without treatment indications",
            "risk_group": "Observation group",
            "treatment_plans": [
                {
                    "treatment_line": "Initial management",
                    "patient_subgroup": "Asymptomatic patients",
                    "plan_name": "Observation",
                    "plan_details": "No immediate treatment; monitor for symptom development",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard approach"
                }
            ]
        },
        {
            "staging_criteria": "Active disease requiring treatment",
            "risk_group": "Treatment-naive",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General population",
                    "plan_name": "Cladribine or Pentostatin",
                    "plan_details": "Purine analogs: Cladribine (IV/SC) or Pentostatin",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General population",
                    "plan_name": "Cladribine + Rituximab",
                    "plan_details": "Combination therapy for higher CR/MRD negativity rates",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Frail patients, active infection, or purine analog intolerance",
                    "plan_name": "Vemurafenib + Anti-CD20 mAb",
                    "plan_details": "Vemurafenib with Obinutuzumab/Rituximab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed disease",
            "risk_group": "Relapse >2 years after initial therapy",
            "treatment_plans": [
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "Late relapse",
                    "plan_name": "Retreatment with purine analog ± Rituximab",
                    "plan_details": "Initial purine analog or alternative purine analog + rituximab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/refractory disease",
            "risk_group": "Relapse ≤2 years or refractory",
            "treatment_plans": [
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "BRAF V600E+ patients",
                    "plan_name": "Vemurafenib + Rituximab",
                    "plan_details": "Targeted therapy combination",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "BRAF V600E+ patients",
                    "plan_name": "Dabrafenib + Trametinib",
                    "plan_details": "BRAF/MEK inhibitor combination",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "General population",
                    "plan_name": "Ibrutinib or Zanubrutinib",
                    "plan_details": "BTK inhibitors",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "BRAF inhibitor-resistant",
                    "plan_name": "Venetoclax + Rituximab",
                    "plan_details": "BCL-2 inhibitor combination",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "All patients",
                    "plan_name": "Clinical Trials",
                    "plan_details": "Encouraged participation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Progressive disease",
            "risk_group": "After prior therapies",
            "treatment_plans": [
                {
                    "treatment_line": "Later-line treatment",
                    "patient_subgroup": "Not previously exposed",
                    "plan_name": "BRAF/MEK inhibitors",
                    "plan_details": "For patients without prior BRAF/MEK inhibitor exposure",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                },
                {
                    "treatment_line": "Later-line treatment",
                    "patient_subgroup": "General population",
                    "plan_name": "BTK inhibitors",
                    "plan_details": "Ibrutinib or Zanubrutinib",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "Later-line treatment",
                    "patient_subgroup": "All patients",
                    "plan_name": "Clinical Trials",
                    "plan_details": "Preferred approach",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "BRAF V600E: Diagnostic for classical HCL; predicts response to BRAF inhibitors. IGHV4-34 Rearrangement: Associated with poor prognosis and resistance to purine analogs. MAP2K1 Mutations: Aids differential diagnosis of HCL variant when BRAF wild-type. MRD Monitoring: Post-treatment negativity correlates with prolonged remission in relapsed disease."
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：毛细胞白血病.txt"
}